Skip to main content
Equibles
AIDX logo

AIDX · 20/20 Biolabs, Inc. · Metrics

Track AIDX — free

Use AIDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AIDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.34 -0.04 (-10.53%) At close · Oct 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The accompanying condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.”
View the 10-Q filed Aug 14, 2026
Market Cap
$5.31M
Shares
12.77M
Volume · Oct 5 119.88K Avg daily vol (3M) 92.73K

AIDX metrics

52 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.38
Market cap
$5.31M

Price action

20 metrics
Price change (1W)
-11.6%
Price change (30D)
-34.5%
Price change (3M)
-38.7%
Price change (6M)
-79.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
131.4%
Annualized volatility (3M)
76.0%
Beta
0.6
RSI (14D)
29.9
Price vs SMA 50
-23.4%
Price vs SMA 200
—
Avg volume (3M)
92,729
Relative volume
0.7
Average dollar volume
$48,129

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
12.77M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.6×
reciprocal yield 38.4%
P / book
3.3
reciprocal yield 30.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-109.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
31.5%
Operating margin
-215.7%
Trailing 12 months
Net margin
-285.0%
Gross profit (TTM)
$643,094
Operating profit (TTM)
−$4.40M
Net income (TTM)
−$5.81M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
+36.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.04M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+123.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-358.8%
Return on assets
-95.0%
Debt / equity
—
Current ratio
2.0
EBITDA (TTM)
−$4.35M
Free cash flow (TTM)
—
Quick ratio
1.9
Interest coverage
-6.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.55M
Latest balance sheet
Cash & equivalents
$4.55M
Total assets
$6.12M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.79M
Capital expenditures (TTM)
—
R&D (TTM)
$672,728
SG&A (TTM)
$4.37M
Stock compensation (TTM)
$756,620
R&D / revenue
33.0%
Stock compensation / revenue
37.1%

Ownership (13F)

3 metrics
13F filers
15
13F filer change QoQ
+8
Institutional ownership
4.2%

Short interest

3 metrics
Short interest
0.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
31 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1139685 CUSIP 90138K101 Visit website Investor relations